Cargando…
Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives
Small-molecule agonism of peroxisome proliferator-activated receptor α (PPARα), a ligand-activated transcriptional factor involved in regulating fatty acid metabolism, is an important approach for treating dyslipidemia. Here, we determined the structures of the ligand-binding domain (LBD) of PPARα i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203124/ https://www.ncbi.nlm.nih.gov/pubmed/32376995 http://dx.doi.org/10.1038/s41598-020-64527-x |
_version_ | 1783529816510693376 |
---|---|
author | Yoshida, Takuya Oki, Hiroya Doi, Michihiro Fukuda, Syohei Yuzuriha, Tomohiro Tabata, Ryotaro Ishimoto, Kenji Kawahara, Kazuki Ohkubo, Tadayasu Miyachi, Hiroyuki Doi, Takefumi Tachibana, Keisuke |
author_facet | Yoshida, Takuya Oki, Hiroya Doi, Michihiro Fukuda, Syohei Yuzuriha, Tomohiro Tabata, Ryotaro Ishimoto, Kenji Kawahara, Kazuki Ohkubo, Tadayasu Miyachi, Hiroyuki Doi, Takefumi Tachibana, Keisuke |
author_sort | Yoshida, Takuya |
collection | PubMed |
description | Small-molecule agonism of peroxisome proliferator-activated receptor α (PPARα), a ligand-activated transcriptional factor involved in regulating fatty acid metabolism, is an important approach for treating dyslipidemia. Here, we determined the structures of the ligand-binding domain (LBD) of PPARα in complex with 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivatives, which were recently identified as PPARα-selective activators with markedly different structures from those of the well-known PPARα agonists fibrates. The crystal structures of the complexes showed that they form a canonical hydrogen-bond network involving helix 12 in the LBD, which is thought to be essential for PPARα activation, as also observed for fibrates. However, the phenyl side chain of the compounds occupies a small cavity between Ile272 and Ile354, which is rarely accessed by fibrates. This unique feature may be essential for subtype selectivity and combine with the well-characterized binding mode of fibrates to improve activity. These findings demonstrate the advantage of using 1H-pyrazolo-[3,4-b]pyridine as a skeleton of PPARα agonists and provide insight into the design of molecules for treating dyslipidemia. |
format | Online Article Text |
id | pubmed-7203124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-72031242020-05-12 Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives Yoshida, Takuya Oki, Hiroya Doi, Michihiro Fukuda, Syohei Yuzuriha, Tomohiro Tabata, Ryotaro Ishimoto, Kenji Kawahara, Kazuki Ohkubo, Tadayasu Miyachi, Hiroyuki Doi, Takefumi Tachibana, Keisuke Sci Rep Article Small-molecule agonism of peroxisome proliferator-activated receptor α (PPARα), a ligand-activated transcriptional factor involved in regulating fatty acid metabolism, is an important approach for treating dyslipidemia. Here, we determined the structures of the ligand-binding domain (LBD) of PPARα in complex with 1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid derivatives, which were recently identified as PPARα-selective activators with markedly different structures from those of the well-known PPARα agonists fibrates. The crystal structures of the complexes showed that they form a canonical hydrogen-bond network involving helix 12 in the LBD, which is thought to be essential for PPARα activation, as also observed for fibrates. However, the phenyl side chain of the compounds occupies a small cavity between Ile272 and Ile354, which is rarely accessed by fibrates. This unique feature may be essential for subtype selectivity and combine with the well-characterized binding mode of fibrates to improve activity. These findings demonstrate the advantage of using 1H-pyrazolo-[3,4-b]pyridine as a skeleton of PPARα agonists and provide insight into the design of molecules for treating dyslipidemia. Nature Publishing Group UK 2020-05-06 /pmc/articles/PMC7203124/ /pubmed/32376995 http://dx.doi.org/10.1038/s41598-020-64527-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Yoshida, Takuya Oki, Hiroya Doi, Michihiro Fukuda, Syohei Yuzuriha, Tomohiro Tabata, Ryotaro Ishimoto, Kenji Kawahara, Kazuki Ohkubo, Tadayasu Miyachi, Hiroyuki Doi, Takefumi Tachibana, Keisuke Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives |
title | Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives |
title_full | Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives |
title_fullStr | Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives |
title_full_unstemmed | Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives |
title_short | Structural Basis for PPARα Activation by 1H-pyrazolo-[3,4-b]pyridine Derivatives |
title_sort | structural basis for pparα activation by 1h-pyrazolo-[3,4-b]pyridine derivatives |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203124/ https://www.ncbi.nlm.nih.gov/pubmed/32376995 http://dx.doi.org/10.1038/s41598-020-64527-x |
work_keys_str_mv | AT yoshidatakuya structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT okihiroya structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT doimichihiro structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT fukudasyohei structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT yuzurihatomohiro structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT tabataryotaro structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT ishimotokenji structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT kawaharakazuki structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT ohkubotadayasu structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT miyachihiroyuki structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT doitakefumi structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives AT tachibanakeisuke structuralbasisforpparaactivationby1hpyrazolo34bpyridinederivatives |